Peripheral neuropathy ranks among the most common dose-limiting and disabling side-effect of oxaliplatin (OXA)-based chemotherapy. The aim of this prospective, multicentre study was to define early clinical and neurophysiological markers that may help to identify patients at risk of developing severe, treatment emergent, cumulative OXA-induced peripheral neuropathy (OXAIPN)

Velasco, R., Bruna, J., Briani, C., Argyriou, A., Cavaletti, G., Alberti, P., et al. (2013). Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY, 85(4), 392-398 [10.1136/jnnp-2013-305334].

Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients

CAVALETTI, GUIDO ANGELO;ALBERTI, PAOLA;FRIGENI, BARBARA;Cortinovis, D;Cazzaniga, M;
2013

Abstract

Peripheral neuropathy ranks among the most common dose-limiting and disabling side-effect of oxaliplatin (OXA)-based chemotherapy. The aim of this prospective, multicentre study was to define early clinical and neurophysiological markers that may help to identify patients at risk of developing severe, treatment emergent, cumulative OXA-induced peripheral neuropathy (OXAIPN)
Articolo in rivista - Articolo scientifico
Neurooncology; Oncology; EMG; Neuropathy
English
2013
85
4
392
398
none
Velasco, R., Bruna, J., Briani, C., Argyriou, A., Cavaletti, G., Alberti, P., et al. (2013). Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY, 85(4), 392-398 [10.1136/jnnp-2013-305334].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/47426
Citazioni
  • Scopus 122
  • ???jsp.display-item.citation.isi??? 111
Social impact